Начало・Списък с акции・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Отворен

СекторЗдравеопазване

26.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.01

Максимум

27.12

Ключови измерители
By Trading Economics
Приходи	93M -92M
Продажби	78M 214M
EPS	-0.9
Марж на печалбата	-42.991
Служители	1,371
EBITDA	94M -61M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+88.91% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	178M 2.6B
Предишно отваряне	26.85
Предишно затваряне	26.85

Настроения в новините

By Acuity

50%

135 / 340 Класиране в Healthcare

Ultragenyx Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.08.2026 г., 19:36 ч. UTC

News

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

10.08.2026 г., 19:16 ч. UTC

News

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.

7.08.2026 г., 20:03 ч. UTC

News

Ultragenyx Pharmaceutical reported a loss of -$0.90 per share, beating estimates. Revenue of $214 million also exceeded expectations, but shares are trading roughly flat.

6.08.2026 г., 23:21 ч. UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, showing unusual strength despite remaining below their 20-day moving average.

5.08.2026 г., 19:52 ч. UTC

News

Ultragenyx shares are lower after Wells Fargo cut its price target to $45. The company reported an EPS loss of $0.90, exceeding expectations.

4.08.2026 г., 23:02 ч. UTC

News

Ultragenyx Pharmaceutical reported second-quarter revenue of $214 million and narrowed its net loss to $92 million, with shares trading higher in after-market hours.

3.08.2026 г., 22:51 ч. UTC

Ultragenyx Pharmaceutical shares are trading roughly flat after-market. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

31.07.2026 г., 19:52 ч. UTC

Correlated Moves

Ultragenyx Pharmaceutical is lower today amid a decline in the Biotechnology sub-sector, with shares near the lower end of their one-month range.

30.07.2026 г., 19:58 ч. UTC

Correlated Moves

Ultragenyx rises, supported by SPDR S&P Biotech ETF gains.

29.07.2026 г., 18:43 ч. UTC

Ultragenyx Pharmaceutical is lower today, continuing a decline amid broader market pressures from rising crude oil prices and geopolitical tensions.

28.07.2026 г., 19:03 ч. UTC

Ultragenyx Pharmaceutical Inc shares are trading lower, reflecting a challenging performance backdrop amid strength in U.S. mega-cap stocks. No specific news was identified.

27.07.2026 г., 19:07 ч. UTC

Ultragenyx Pharmaceutical Inc shares are higher as crude oil prices decline, easing geopolitical concerns. No specific company news was identified for the move.

24.07.2026 г., 19:51 ч. UTC

Ultragenyx Pharmaceutical Inc shares are declining, continuing a trend of lower daily closes. Broader market volatility and new tariffs may be contributing factors.

22.07.2026 г., 19:36 ч. UTC

Ultragenyx Pharmaceutical shares are declining amid rising crude oil prices due to U.S.-Iran tensions. The stock remains below its 20-day moving average.

21.07.2026 г., 19:22 ч. UTC

Correlated Moves

Rising amid broader market gains and SPDR S&P Biotech support.

20.07.2026 г., 19:17 ч. UTC

Correlated Moves

Ultragenyx Pharmaceutical is declining amid a broader downturn in the Biotechnology sector, continuing a trend of seven consecutive lower sessions.

Сравнение с други в отрасъла

Ценова промяна

Ultragenyx Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

88.91% нагоре

12-месечна прогноза

Среден 50.93 USD 88.91%

Висок 96 USD

Нисък 27 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Ultragenyx Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Ultragenyx Pharmaceutical Inc през последните 3 месеца.

Настроение

By Acuity

135 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.